Allogene Therapeutics Unveils Cell Forge 1, a Uniquely Designed Manufacturing Facility to Deliver Al | ALLO Message Board Posts


Allogene Therapeutics, Inc.

  ALLO website

ALLO   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message    Post Message    Post a Reply return to message boardtop of board
Msg  3 of 4  at  4/16/2022 12:08:55 PM  by

jerrykrause


Allogene Therapeutics Unveils Cell Forge 1, a Uniquely Designed Manufacturing Facility to Deliver AlloCAR T Products

 Pharma & Healthcare Monitor Worldwide
 
 

Allogene Therapeutics Unveils Cell Forge 1, a Uniquely Designed Manufacturing Facility to Deliver AlloCAR T™ Products

 
 

Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer, today announced the virtual unveiling of its manufacturing facility, Cell Forge 1 (CF1), located in Newark, California. The 136,000-square-foot facility is designed to support clinical trial and potential commercial production and worldwide distribution of allogeneic CAR T cell products for blood cancers and solid tumors. The virtual platform, designed to create an interactive and engaging CF1 virtual experience, includes welcome remarks from Allogenes President, Chief Executive Officer and Co-Founder, David Chang, M.D., Ph.D., corporate and scientific videos, a 360 virtual tour of the facility, and a patient gallery.

A Media Snippet accompanying this announcement is available by clicking on the image or link below:

Cell Forge 1 is a critical piece of our strategy for revolutionizing CAR T cancer therapy. As we prepare for our first AlloCAR T pivotal trial in mid-2022, we will draw on the capabilities of this state-of-the-art facility to meet product demand while maintaining important quality controls, said Alison Moore, Ph.D., Chief Technical Officer of Allogene. We believe this is an ideal time to bring the facility online. Cell Forge 1 is uniquely designed to grow with Allogene as we expand our pipeline, prepare for future regulatory filings, and scale up production for potential commercial distribution.

CF1 includes modular production suites, which are flexible and adaptable for growth. It also includes space for quality control testing, an environmental testing lab, and an advanced data system infrastructure, as well as administrative and warehouse space.

Environmental sustainability was a key element of building design, including features that allow for energy savings, water conservation, and reduced greenhouse gas emissions. CF1 is designed to be a fully electric facility 100% powered by renewable solar and wind power aimed at earning LEED Gold certification for design and operation.

In designing Cell Forge 1 we sought to prioritize adaptability, sustainability, and collaboration. CF1 is future-facing and intended to support scalable production of AlloCAR T cells, said Ben Beneski, Vice President and CF1 Site Head at Allogene. We expect the facility to enhance innovation across all facets of manufacturing, allowing Allogene to deliver potential lifesaving cancer treatments to more patients. We are grateful to everyone, both at Allogene and in the community, who brought this vision to reality.

External partners and supporters who were critical in the construction and development of CF1: the City of Newark, Dome Construction, CRB, RIOS, and Savills.

Located in the East Bay, Cell Forge 1 is in proximity to Allogene Therapeutics South San Francisco headquarters, allowing for close exchange among, manufacturing, process development, research and corporate teams. To learn more about what this new facility means for the future of Allogene and the potential impact it will have on those living with cancer visit the Cell Forge 1 Manufacturing hub on Allogenes website. The video and images embedded into this press release above are also available on the site: www.cf1.com .

About Allogene Therapeutics

Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T) products for cancer. Led by a management team with significant experience in cell therapy, Allogene is developing a pipeline of off-the-shelf CAR T cell candidates with the goal of delivering readily available cell therapy on-demand, more reliably, and at greater scale to more patients.

 


     e-mail to a friend      printer-friendly     add to library      
|  
Recs: 0  
   Views: 0 []
Previous Message  Next Message    Post Message    Post a Reply return to message boardtop of board




Financial Market Data provided by
.
Loading...